Entera Bio Ltd. Ordinary Shares
ENTX
Closed
$1.63
Closed
-(-)
At close
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply
About
Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. The firm developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.
Key stats
Open
$1.69
Volume
105.05K
Market cap
$83.79M
Prev. close
$1.70
Impl / hst vl
-
Open interest
$0.00
$1.61
Day’s Range
$1.71
$0.91
52W Range
$2.78
Valuation
44
Valuation score
Fairly Valued
P/E
-
P/S
-
P/B
7.84
Current ratio
7.93
Debt / Equity
-0.39
ROE
-87.97%
Gross margin
-
Income growth
16.21%
FCF growth
66.13
Analysts estimates
Consensus rating
Buy
The average rating from top 4 analysts indicates that stock is expected to perform in line with the market
Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$9.18
The top 3 analysts forecasts that 12-month price may increase by 463.19%, with a low of $9.09 and a high of $9.45
$9.09
Low
$9.18
Avg
$9.45
High
Current price
Earnings
Q1 ‘26 revenue
$0.00
Q1 ‘26 net income
-$3.51M
Revenue
Net income
Previous EPS
-$0.07
Estimate EPS
-$0.08
Actual EPS
Estimate EPS
Explore the Healthcare sector
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply